Furthermore, based on TCGA data sets the authors proved that BLCA patients expressing the wild-type isoform of filaggrin presented less overall survival than patients expressing mutated forms of the barrier protein, consistent with the fact that higher tumor mutation burden favors responses to immunotherapy (133). This evidence concerns the gene FLG and neoplasm.